AVTR (Avantor) 6-Month Share Buyback Ratio : -0.13% (As of Mar. 2025 )

View and export this data going back to 2019. Start your Free Trial

What is Avantor 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Avantor's current 6-Month Share Buyback Ratio was -0.13%.

Competitive Comparison of Avantor's 6-Month Share Buyback Ratio

For the Medical Instruments & Supplies subindustry, Avantor's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avantor's 6-Month Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avantor's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Avantor's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Avantor 6-Month Share Buyback Ratio Calculation

Avantor's 6-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Sep. 2024 )
	=	(680.600	-	681.500)	/	680.600
	=	-0.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avantor (NYSE:AVTR) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Avantor 6-Month Share Buyback Ratio Related Terms

Avantor Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avantor Inc (NYSE:AVTR) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

AVG:Germany AVTR:Austria

Address

100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.avantorsciences.com

Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.

Executives

Gregory L Summe	director	C/O GLEN CAPITAL PARTNERS LLC, 800 SOUTH STREET, SUITE 160, WALTHAM MA 02453
Joseph R Massaro	director	5725 DELPHI DRIVE, TROY MI 48098
Jonathan M Peacock	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lan Kang	director	100 MATSONFORD ROAD, RADNOR PA 19087
James Bramwell	officer: EVP, Strategic Partners	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Steven W Eck	officer: SVP & Chief Accounting Officer	C/O CSS INDUSTRIES, INC., 450 PLYMOUTH ROAD, SUITE 300, PLYMOUTH MEETING PA 19462
Christophe Couturier	officer: See Remarks	9 FOURTH AVENUE, C/O OVASCIENCE INC., CAMBRIDGE MA 02451
Benoit Gourdier	officer: EVP, Biopharma Production	100 MATSONFORD ROAD, RADNOR PA 19087
Frederic Vanderhaegen	officer: EVP, Europe	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Brittany Hankamer	officer: EVP, Chief HR Officer	100 MATSONFORD ROAD, RADNOR PA 19087
R. Brent Jones	officer: EVP, Chief Financial Officer	C/O PALL CORPORATION, 25 HARBOR PARK DRIVE, PORT WASHINGTON NY 11050
Claudius Sokenu	officer: EVP, Chief Legal & Compliance	C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, BLUE BELL PA 19422
Randy Lee Stone	officer: EVP, Proprietary Products	974 CENTRE ROAD, CRP 730, WILMINGTON DE 19805
Gerard Brophy	officer: EVP, Biopharma Production	C/O AVANTOR, INC., 100 MATSONFORD ROAD, RADNOR PA 19087
Kitty Sahin	officer: EVP, Strategy&Corp Development	100 MATSONFORD ROAD, RADNOR PA 19087